Discovering Breakthrough Treatments for Human Disease. Discovering Breakthrough Treatments for Human Disease
|
|
- Gyles McKenzie
- 5 years ago
- Views:
Transcription
1 Patient Reported Outcomes in Oncology Trials Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Discovering Breakthrough Treatments for Human Disease Discovering Breakthrough Treatments for Human Disease 2015 Lexicon Pharmaceuticals, Inc. Slide 0
2 Patient Reported Outcomes: A Personal Story 2015 Lexicon Pharmaceuticals, Inc. Slide 1
3 A Personal Story A family member participated in a clinical trial of cetuximab With complete response of stage IV adenocarcinoma of the lung There was extensive improvement - Better mood - More energy - Increased optimism - Good overall survival There was no change in patient reported outcomes! 2015 Lexicon Pharmaceuticals, Inc. Slide 2
4 Cetuximab with Chemotherapy in Lung Cancer No significant difference in quality of life between the two treatment arms was reported by the two relevant studies. The quality of the evidence is high for overall survival and one-year survival rate, but low for most secondary outcomes. Yang ZY et al. Cochrane Database Syst Rev Nov 17;11:CD doi: / CD pub Lexicon Pharmaceuticals, Inc. Slide 3
5 Why are Quality of Life Benefits Not Detected? The most common approach to questionnaire development is to be as comprehensive as possible However, this introduces a lot of items that will not be relevant to many patients and may not respond to effective treatment Moreover, grading is often on abbreviated scales that only capture large changes - Moderate vs. severe A general tendency is to provide equal weighting to all questions, even though one or two domains may be the most important 2015 Lexicon Pharmaceuticals, Inc. Slide 4
6 Example: the FACT-L Questionnaire 2015 Lexicon Pharmaceuticals, Inc. Slide 5
7 Additional Questions: The FACT-L 2015 Lexicon Pharmaceuticals, Inc. Slide 6
8 Where Should we Focus? An important aspect of cancer treatment is emotional well-being - Although this is complicated by many issues unrelated to treatment, even temporary success in the fight against cancer is meaningful to patients Success may manifest itself in satisfaction measures or overall global assessments 2015 Lexicon Pharmaceuticals, Inc. Slide 7
9 Relevant Questions from the FACT-L 2015 Lexicon Pharmaceuticals, Inc. Slide 8
10 Key Lessons A comprehensive questionnaire may include a lot of information unrelated to the intervention in a clinical trial Understanding patient priorities (the most relevant domains) can help appreciate benefit Emotional well-being may be particularly important - Although more work is needed to understand specifically how it relates to the fight against cancer - Measures of patient satisfaction or global assessments of the clinical trial experience may be helpful 2015 Lexicon Pharmaceuticals, Inc. Slide 9
11 A Potential Option: Patient Interviews A comprehensive questionnaire aims to quantify quality of life - The patient becomes a number Semi-structured interviews are less quantitative in nature but may be more informative - Knowing patient priorities - Understanding how symptoms are connected to each other - Appreciating their view of benefit/risk - Developing a vision of clinically meaningful change Listen to the voice of the patient 2015 Lexicon Pharmaceuticals, Inc. Slide 10
12 Quality of Life as a Story Rather than a Statistic A typical approach in patient reported outcomes research is to apply an instrument and develop an overall score This approach has significant limitations - You might select the wrong instrument - You could rely too much on a p-value to make conclusions - It may be difficult to interpret clinically meaningful change - You may not learn about the relationships between symptoms 2015 Lexicon Pharmaceuticals, Inc. Slide 11
13 Quality of Life as a Story Consider conducting semi-structured interviews in your clinical trial - Let the patients tell their stories - Have an expert guide the discussion, ensuring that broad domains are addressed - Read the transcripts or watch the videos - Gain a better clinical understanding of the trial experience 2015 Lexicon Pharmaceuticals, Inc. Slide 12
14 Example: Development of Telotristat Etiprate Telotristat etiprate is an investigational agent being developed for the treatment of carcinoid syndrome Carcinoid syndrome is the result of excessive serotonin production by metastatic neuroendocrine tumors - Diarrhea, abdominal pain - Facial flushing - Destruction of heart valves - Fibrosis in the abdomen Telotristat etiprate is intended to treat carcinoid syndrome by reducing serotonin production within the cancer cell 2015 Lexicon Pharmaceuticals, Inc. Slide 13
15 Telotristat Etiprate Phase 2 Results: Reduction in Bowel Movement Frequency Kulke et al. Endocr Relat Cancer Oct;21(5): Lexicon Pharmaceuticals, Inc. Slide 14
16 Telotristat Etiprate Phase 2 Patient Interviews 11 patients interviewed Gastrointestinal symptoms affected their everyday lives - Sleep -Fatigue - Function Ability to socialize, travel, or participate in usual activities or hobbies Improvements reported for several symptoms - Diarrhea (n=9) - Abdominal pain (n=5) - Abdominal cramping (n=4) - Facial flushing (n=4) -Gas (n=3) There was no worsening of symptoms Kulke et al Lexicon Pharmaceuticals, Inc. Slide 15
17 Telotristat Etiprate Phase 2 Individual Response # Bowel Movements Flushing Episodes Day -4 Day -3 Day -2 Day -1 Day 1 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 12 Day 13 Day 14 Day 15 Day 17 Day 18 Day 19 Day 20 Day 21 Day 22 Day 23 Day 24 Day 25 Day 26 Day 27 Day 28 Baseline Drug Initiation Drug Discontinued Drug Reinstated Lapuerta et al. Clinical Investigation 2015;5(5): Lexicon Pharmaceuticals, Inc. Slide 16
18 Individual Patient Interview #1 Extensive detail provided - Pleased with the initial response - Concerned about temporary interruption of therapy - Relieved to resume drug She provided a perspective on several important themes - Clinically meaningful change - Overall magnitude of potential response - Impact of symptom relief on other domains 2015 Lexicon Pharmaceuticals, Inc. Slide 17
19 Telotristat Etiprate Phase 2: Individual Response #2 10 Mean Number of BM Baseline WEEK RUN-IN Dose (mg tid) Adequate Relief No No No No Yes 2015 Lexicon Pharmaceuticals, Inc. Slide 18
20 Individual Patient Interview #2 Improvement in several symptoms - Gastrointestinal symptoms - Night sweats - Emotional well-being He provided a perspective on several themes - Social function - How a reduction in bowel movement frequency may relate to absorption of food and medication 2015 Lexicon Pharmaceuticals, Inc. Slide 19
21 Telotristat Etiprate Phase 3 Program: TELESTAR Stable-dose somatostatin analog (SSA) R 1:1:1 Telotristat etiprate 500 mg TID + SSA Telotristat etiprate 250mg TID + SSA Telotristat etiprate 500mg TID + SSA (n=~120) Placebo TID + SSA 3 to 4 week Run-In *1 week blinded titration period 12-week treatment period* 36-week extension* (Open-label) Enrollment Criteria: Carcinoid Syndrome with > 4 Bowel movements/day Patient Interviews 2015 Lexicon Pharmaceuticals, Inc. Slide 20
22 Relevance of Interviews to Clinical Development Selection of patient reported outcomes for phase 3 - Question on sleep - Global assessments Planning additional interviews in phase 3 - Understanding unmet need - Providing perspective on primary endpoint - Directing focus to specific items of EORTC questionnaire - Supporting vision of clinically meaningful change Appreciating benefit/risk 2015 Lexicon Pharmaceuticals, Inc. Slide 21
23 Limitations of the Interview Approach Sample size is small Statistical interpretation may be limited Publication opportunities are unclear Unlikely to make a direct contribution to drug labeling 2015 Lexicon Pharmaceuticals, Inc. Slide 22
24 Conclusions Quality of life should be a story and not just a statistic - A more profound understanding can come from a detailed examination of different items and individual cases Focus on specific domains most likely to respond to therapy Consider global assessment of therapy Consider semi-structured interviews Listen to the voice of the patient 2015 Lexicon Pharmaceuticals, Inc. Slide 23
Clinical Development in the Treatment of Carcinoid Syndrome. Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer
Clinical Development in the Treatment of Carcinoid Syndrome Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Carcinoid Syndrome Heart Pulmonic and tricuspid valve thickening Stenosis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationPRESS RELEASE. Beaumont et al. Pancreas Journal 2012 ; 41(3) : / 5
PRESS RELEASE Ipsen receives approval from European Commission for Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue
More informationTelotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP
Telotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine
More informationImpact of Functioning Metastatic Neuroendocrine Tumors
Clinical Overview and Treatment Advances in Carcinoid Syndrome Sponsored by Lexicon Pharmaceuticals Impact of Functioning Metastatic Neuroendocrine Tumors Evaluation & Management 1 Presentation objectives
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Niaspan Name of Active Ingredient: Page: Niacin extended-release
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationTUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca
TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationProduct: Femmerol. Client: Solutions for Women, LLC 315 North Village Avenue New York, (516)
CLINICAL TRIAL In 2002 the company completed an IRB (Institutional Review Board) Prospective, Randomized, Placebo-Controlled Clinical Trial. In Conclusion: Femmerol is effective in relieving a number of
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationPain Notebook NAME PHONE. Three Hole Punch Here Three Hole Punch Here. Global Pain Initiative 2018 Ver 1.0
Pain Notebook Three Hole Punch Here Three Hole Punch Here NAME EMAIL PHONE Global Pain Initiative 2018 Ver 1.0 What is pain? Pain is a bad sensation that tells you something is wrong. Pain falls into two
More informationOVERALL CLINICAL BENEFIT
noted that there are case reports of a rebound effect upon discontinuation of ruxolitinib (Tefferi 2012), although this was not observed in either the COMFORT I or COMFORT II studies. Therefore, perc considered
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
differ and that they each has a unique mechanism of action. As such perc considered that it would be important for clinicians and patients to be able to choose either drug as a first-line treatment option.
More informationBackground. 2 5/30/2017 Company Confidential 2015 Eli Lilly and Company
May 2017 Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in
More informationAt the outset, we want to clear up some terminology issues. IBS is COPYRIGHTED MATERIAL. What Is IBS?
1 What Is IBS? At the outset, we want to clear up some terminology issues. IBS is the abbreviation that doctors use for irritable bowel syndrome, often when they are talking about people with IBS. We will
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationConventional therapy n=32. RGI-C Score (Primary Endpoint) LS Mean* (0.83, 1.45) P< Substantial healing, % patients (RGI-C +2.
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationPRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse
PRO ASSESSMENT IN CANCER TRIALS Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse DISCLOSURES Emiliano Calvo has reported no conflicts of interest
More informationTonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia
September 29, 2014 Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia Conference Call Today at 8:30 a.m. ET NEW YORK, Sept. 29, 2014
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationSupporting Recovery: The Role of the Family
Supporting Recovery: The Role of the Family Resources and Additional Support How can you help a relative who has co-occurring psychiatric and substance use disorders? Family members can play a key role
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationMitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006
Mitchell H. Gold, M.D. President and CEO 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006 1 Dendreon Corporation: A Biotechnology Company on the Verge of Changing the Way
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationClinical Trial Exit Interviews
Clinical Trial Exit Interviews Presented at the Clinical Outcome Assessments: Establishing and Interpreting Meaningful Within-Patient Change Meeting The Duke-Margolis Center for Health Policy, Washington,
More informationPhase 2b/3 Topline Trial Results
Phase 2b/3 Topline Trial Results RP-G28 For the Treatment of Lactose Intolerance March 2017 Forward - Looking Statement To the extent that statements contained in this presentation are not descriptions
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationInvestigating Plinabulin as Immune-Modifying Therapy for Non-Small Cell Lung Cancer (NSCLC)
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/project-oncology/beyondspring-birnholzmita/9543/
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationNHC Webinar Series on Clinical Outcome Assessments. Patient-Reported Outcomes and Patient-Centered Outcomes: Is There a Difference?
NHC Webinar Series on Clinical Outcome Assessments Patient-Reported Outcomes and Patient-Centered Outcomes: Is There a Difference? NOVEMBER 7, 2018 Outline Why are we having this webinar? Introduction
More informationAddressing Content Validity of PRO Measures: The Unique Case of Rare Diseases
Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the Kakkis EveryLife Foundation, for educational purposes only. They are for use by drug development professionals and
More informationJ. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health
J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationGATTEX (Teduglutide) for Injection REMS Program: Prescriber Education
GATTEX (Teduglutide) for Injection REMS Program: Prescriber Education Shire-NPS Pharmaceuticals, Inc. 300 Shire Way, Lexington, MA 02421 A REMS (Risk Evaluation and Mitigation Strategy) is a program required
More informationDeveloping treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need
Developing treatment options for patients with rare gastrointestinal and endocrine disorders and unmet medical need Luke Beshar, senior vice president and chief financial officer BioNJ BioPartnering 2011
More informationFrequently Asked Questions FAQS. NeuroStar TMS Therapies
Frequently Asked Questions FAQS NeuroStar TMS Therapies Provided by Dr Terrence A. Boyadjis MD 790 E Market Street Suite 245 West Chester, PA 19382 610.738.9576 FAQS About TMS Therapies Page 1 NeuroStar
More informationDr. Gary Malstrom B.Sc.(Hon.), D.C., C.Ac Brant Street, Burlington, Ontario L7R 2J9 (905) Fax (905)
Dr. Gary Malstrom B.Sc.(Hon.), D.C., C.Ac. Personal History: Name: Address: City: Province: Postal Code: Birth date: day /month /year Age: Sex: M F Home Phone: Business Phone: Cell Phone: E-mail: Health
More informationSoul of leadership workshop. Patricia E. Molina, MD, PhD What I learned
Soul of leadership workshop Patricia E. Molina, MD, PhD What I learned Minds Our minds grow in relationships with other minds. We can t grow without relationships. We are only potential Concepts Listening:
More informationAUSTRALIAN PRODUCT INFORMATION 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationResults Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy
Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH) Results Confirm and Extend 40-Week Findings that
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
Overall, perc considered that everolimus aligned with patient values. Patient advocacy group input on everolimus indicated that patients with pnets value the outcome of progression-free survival as a measure
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationCreating a Child Self-Report Measure of Adverse Events Related to Cancer Treatment; Providing a Voice for the Child
Creating a Child Self-Report Measure of Adverse Events Related to Cancer Treatment; Providing a Voice for the Child Casey Hooke, PhD, RN, PCNS, CPON University of Minnesota School of Nursing Pamela Hinds,
More informationPalliative Care in Patients with Brain Tumors: How to maintain hope and quality of life, even when treatments fail
Tobias Walbert MD PhD MPH Assistant Professor Neurology Wayne State University Henry Ford Hospital Detroit twalber1@hfhs.org Palliative Care in Patients with Brain Tumors: How to maintain hope and quality
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More informationWhat makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012
What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 Disclaimer The opinions expressed in this presentation and on the following slides are solely
More informationHamilton Depression Rating Scale 17-Item (HAMD 17)
Hamilton Depression Rating Scale -Item ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationFor the Patient: USMAVPEM
For the Patient: USMAVPEM Other Names: Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab U = Undesignated (requires special request) SM = Skin and Melanoma AV = Advanced PEM = Pembrolizumab
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationA RANDOMISED CONTROLLED TRIAL OF CONQUER FEAR DELIVERED IN A GROUP FORMAT
A RANDOMISED CONTROLLED TRIAL OF CONQUER FEAR DELIVERED IN A GROUP FORMAT Nina Moeller Tauber, MSc. in psychology and Ph.D. fellow 1, Professor Robert Bobby Zachariae 1, Associate Professor Mia Skytte
More informationIn Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo Shin Choi 2, and Seung Eun Lee 2. Departments of Surgery, Dongguk University College of Medicine 2
Effect of Rowachol on Prevention of Postcholecystectomy Syndrome after Laparoscopic Cholecystectomy - Prospective multicenter Randomized controlled trial- In Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo
More informationsunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited
sunitinib 12.5mg, 25mg, 37.5mg, 50mg hard capsules (Sutent ) SMC No. (698/11) Pfizer Limited 08 April 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More information10 session activity guide for women s circles
WOMENS CIRCLE Being a Well Woman 10 session activity guide for women s circles Authors: Julie Humbel-Courtney, Jamie Lodermeier-Fay, & Vicki K. Pitstick With Giovanna Taormina and Beth Hossfeld, MFT Week
More informationNorthera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension. September 2010
Northera (droxidopa) Preliminary Findings From Study 301 in Symptomatic Neurogenic Orthostatic Hypotension September 2010 1 2004-2010 Chelsea Therapeutics, Inc. This presentation is being provided for
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationOU Children s Physicians Pediatric Arthritis Center
Please complete the following questionnaire for your child: Patient Name: Birth Date: Parent/Caretaker Name: Primary Care Physician (Full Name, City, & State) Mother s Occupation: Fathers Occupation: Name
More informationCHILDHOOD C 3 HANGE CARE TOOL: PROVIDER REPORT
Date: / / Patient s Project ID# For use as-needed in clinic visits A SURVEY TO LEARN ABOUT A PATIENT S NEEDS AND ABILITIES: Health care providers of children and adolescents aged 5 to 2 How is this patient
More informationDepression in the Elderly. Introduction
Depression in the Elderly Introduction Depression is a common mental disorder that is estimated to be prevalent in 7-12% in adult of over 65 years (Ning, 2009). Like other disease such as diabetes and
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPatient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know?
Patient Reported Outcomes (PROs) in IBD: What Are They and What Does the Clinician Need to Know? Peter D.R. Higgins Director, IBD Program University of Michigan What are PROs? ClinRO Patient- Reported
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationBrisbin Family Chiropractic
Information reviewed with patient: Dr. Initials Today s Date Brisbin Family Chiropractic Name: Sex: Male Female Address: City: Postal Code: Home Ph# Work# Ext# Cell# Preferred number (circle one) Home
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationPain Management Pathway Redesign. Briefing on Patient Journey Mapping approach to patient interviews
Pain Management Pathway Redesign Briefing on Patient Journey Mapping approach to patient interviews Purpose This proposal outlines the approach being undertaken to capture and report patient experience
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More information4. How often do you use all of your energy to accomplish only this activity? [yellow card]
Calgary Sleep Apnea Quality of Life Index (Interviewer) This questionnaire has been designed to find out how you have been doing and feeling over the last 4 weeks. You will be questioned about the impact
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationPatient Reported Outcomes
Date Patient Reported Outcomes Presented by: Ari Gnanasakthy RTI Health Solutions 9 th Feb 2015 RTI Health Solutions Research Triangle Park, NC, USA Ann Arbor, MI, USA Barcelona, Spain Ljungskile, Sweden
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationRESPONSE (NCT )
Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results Abstract #709 Mesa R, Verstovsek S, Kiladjian
More informationNeuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
More information- Amendment accelerates anticipated PROSPER top-line results by two years -
Pfizer Contacts: For Media Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com For Investors Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Astellas Contact: For Media Tyler Marciniak (847) 736-7145
More informationSYNOPSIS. Approved Date: 9 November 2015 Prepared by: Status: Janssen Research & Development, LLC
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationFaculty/Presenter Disclosure
Everything you want to know about helping people living with obesity (in 45 minutes ) An overview of the 5As Team approach to advancing obesity prevention, assessment and management in primary care Denise
More informationSTROKESTRA. Stroke Rehabilitation through Creative Music-Making
STROKESTRA Stroke Rehabilitation through Creative Music-Making Evidence Base Studies have focused on the use of music to promote social interaction, positive mood and lower depression and anxiety. Nayak
More informationThe Self Care: Be Your Best Report A global study on common health conditions and how people practice self care
The Self Care: Be Your Best Report 2018 A global study on common health conditions and how people practice self care Foreword Most of us have woken up recently with some type of pain, a blocked or runny
More informationHEADACHE HISTORY & PROFILE QUESTIONNAIRE
1 HEADACHE HISTORY & PROFILE QUESTIONNAIRE Patient Name: On what part of the head do your headaches start? R Side L Side Either Side Both Sides Back On Top Temples Behind/AroundEyes Forehead Face Neck
More informationrisks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.
risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationLead team presentation Eluxadoline for treating irritable bowel syndrome with diarrhoea (STA)
Public slides Lead team presentation Eluxadoline for treating irritable bowel syndrome with diarrhoea (STA) 1 st Appraisal Committee meeting Committee B, 25th January 2017 Lead team: Nigel Westwood, Anne
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More information